

## Technology Appraisal Committee Meeting (Committee B)

**Minutes:** **Confirmed**

**Date and Time:** Wednesday 5 October 2016, 10am to 5pm

**Venue:** Prospero House  
241 Borough High Street  
London  
SE1 1GA

<b>Present:</b>	1. Dr Amanda Adler 2. Dr Sanjeev Patel 3. Dr Ray Armstrong 4. Dr Jeff Aronson 5. Professor John Cairns 6. Mr Mark Chapman 7. Dr Neil Iosson 8. Dr Rebecca Kearney 9. Christopher O'Regan 10. Professor Stephen Palmer 11. Professor John Poundsford 12. Dr Dani Preedy 13. Dr Nigel De-Kare Silver 14. Dr Marta Soares 15. Professor Ken Stein 16. Mr David Thomson 17. Nigel Westwood	Present for all notes Present for notes 19 to 42 Present for all notes Present for all notes Present for notes 1 to 16 Present for all notes Present for all notes Present for notes 1 to 16 Present for all notes Present for all notes
-----------------	--	--

### In attendance:

Meindert Boysen	Programme Director, National Institute for Health and Care Excellence	Present for notes
Dr Melinda Goodall	Associate Director, National Institute for Health and Care Excellence	Present for all notes
Jeremy Powell	Project Manager, National Institute for Health and Care Excellence	Present for all notes
Glenys Russell	Administrator, National Institute for Health and Care Excellence	Present for all notes
Rosie Lovett	Technical Adviser, National Institute for	Present for notes 19 to 28

	Health and Clinical Excellence	
Jasdeep Hayre	Technical Adviser, National Institute for Health and Clinical Excellence	Present for all notes
Anna Brett	Technical Lead, National Institute for Health and Clinical Excellence	Present for notes 1 to 18
Abitha Senthinathan	Technical Lead, National Institute for Health and Clinical Excellence	Present for notes 19 to 28
Dr Wendy Gidman	Technical Lead, National Institute for Health and Clinical Excellence	Present for Notes 29 to 39
Boglarka Mikudina	Technical Lead, National Institute for Health and Clinical Excellence	Present for notes 40 to 42
Dr Bram Ramaekers	Health Economist, Kleijnen Systematic Reviews	Present for notes 1 to 16
Robert Wolff	Systematic Reviewer, Kleijnen Systematic Reviews	Present for notes 1 to 16
Professor Neil McHugh	Consultant Rheumatologist, University of Bath nominated by the British Society for Rheumatology	Present for notes 6 to 14
Professor Catherine Smith	Prof of Dermatology and Therapeutics, Guys and St Thomas' Hospital, nominated by the British Association of Dermatologists	Present for notes 6 to 14
David Chandler	Chief Executive, Psoriasis & Psoriatic Arthritis Alliance nominated by the Psoriasis & Psoriatic Arthritis Alliance	Present for notes 6 to 14

Nicola Huxley	Associate Research Fellow, Peninsular Technology Assessment Group	Present for notes 19 to 26
Professor Martin Hoyle	Professor of Health Economics, Peninsular Technology Assessment Group	Present for notes 19 to 26
Matt Stevenson	Technical Director, School of Health and Related Research	Present for notes 29 to 37
Inigo Bermejo	Research Associate, School of Health and Related Research	Present for notes 29 to 37

**Non-public observers:**

Edgar Masanga	Business Analyst - Resource Impact Assessment, NICE	Present for all notes
Diogenes Ferreira	European Respiratory Society Fellow in Guideline Methodology, NICE	Present for notes 1 to 39
Jacoline Bouvy	Scientific Adviser, Science Policy & Research, NICE	Present for all notes
Francesca Cerreta	Senior Scientific Officer in EMA Scientific Advice	Present for all notes
Orsolya Balogh	Technical Analyst, Technology Appraisals, NICE	Present for all notes
Thomas Paling	Technical Analyst, Technology Appraisals, NICE	Present for all notes
Ahmed Elsada	Technical Advisor, Technology Appraisals, NICE	Present for all notes

**Notes**

**Welcome**

1. The Chair welcomed all members of the Committee and other attendees present to the meeting. The Chair reviewed the agenda and timescales for the meeting, which included the appraisals of ixekizumab for treating moderate to severe

plaque psoriasis [ID904], lenalidomide for the treatment of multiple myeloma in people who have received at least one prior therapy with bortezomib (partial review of TA171) [ID667], mepolizumab for treating severe eosinophilic asthma [ID798] and ibrutinib for treating chronic lymphocytic leukaemia [ID749].

2. The Chair informed the Committee that it was John Pounsford's last meeting as a Committee member and thanked him for his contributions to the Committee. Jeff Aronson's last meeting will be in November.
3. The Chair informed the Committee of the non-public observers at this meeting: Helen Barnett, Mike Chambers, Chloe Kastoryano, Heather Stegenga and Thomas Wood.
4. Apologies were received from Dr Mark Glover, Anne Joshua, Dr Sanjay Kinra, Professor Ruairidh Milne, Alun Roebuck, Dr Nicky Welton.

## **Any other Business**

5. The Committee were given an update on the progress of other appraisals.

## **Appraisal of ixekizumab for treating moderate to severe plaque psoriasis [ID904]**

### **Part 1 – Open session**

6. The Chair welcomed the invited experts: Professor Neil McHugh, Professor Catherine Smith and David Chandler to the meeting and they introduced themselves to the Committee.
7. The Chair welcomed company representatives from Eli Lilly to the meeting.
8. The Chair asked all Committee members to declare any relevant interests
  - 8.1. Dr Amanda Adler, Dr Sanjeev Patel, Dr Ray Armstrong, Dr Jeff Aronson, Professor John Cairns, Mr Mark Chapman, Dr Neil Iosson, Dr Rebecca Kearney, Professor Stephen Palmer, Professor John Pounsford, Dr Nigel De-Kare Silver, Dr Marta Soares, Professor Ken Stein, Mr David Thomson and Mr Nigel Westwood all declared that they knew of no personal specific financial interest, personal non-specific financial interest, non-personal specific financial interest, non-personal non-specific financial interest, personal specific family interest or personal non-specific family interest for any of the technologies to be considered as part of the appraisal of ixekizumab for treating moderate to severe plaque psoriasis [ID904].
  - 8.2. Mr Chris O'Regan declared a personal specific financial interest before the meeting as his employer (Merck Sharpe and Dohme) manufacture infliximab.
    - 8.2.1. It was agreed that this declaration would prevent Chris O'Regan from participating in this section of the meeting.
9. The Chair asked all NICE Staff to declare any relevant interests.
  - 9.1. All declared that they knew of no personal specific financial interest, personal non-specific financial interest, non-personal specific financial interest, non-personal non-specific financial interest, personal specific

family interest or personal non-specific family interest for any of the technologies to be considered as part of the appraisal of ixekizumab for treating moderate to severe plaque psoriasis [ID904].

10. The Chair asked all other invited guests (assessment group/ERG and invited experts, not including observers) to declare their relevant interests.
  - 10.1. Dr Bram Ramaekers, Robert Wolff and David Chandler declared that they knew of no personal specific financial interest, personal non-specific financial interest, non-personal specific financial interest, non-personal non-specific financial interest, personal specific family interest or personal non-specific family interest for any of the technologies to be considered as part of the appraisal of ixekizumab for treating moderate to severe plaque psoriasis [ID904].
  - 10.2. Professor Catherine Smith declared a non-personal financial interest as her department has received funding from pharmaceutical companies involved in this appraisal.
    - 10.2.1. It was agreed that this declaration would not prevent Professor Catherine Smith from participating in this section of the meeting.
  - 10.3. Professor Neil McHugh declared a personal specific financial interest as he sits on an advisory board for Abbvie and has received research funding from Celgene and Pfizer.
    - 10.3.1. It was agreed that this declaration would not prevent Professor Neil McHugh from participating in this section of the meeting.
11. The Chair introduced the lead team, Ray Armstrong, Sanjeev Patel and Nigel Westwood who gave presentations on the clinical effectiveness and cost effectiveness of ixekizumab for treating moderate to severe plaque psoriasis [ID904].
12. The Chair asked the company representatives whether they wished to comment on any matters of factual accuracy.
13. The Chair explained that "representatives of the press and other members of the public be excluded from the remainder of this meeting having regard to the confidential nature of the business to be transacted, publicity on which would be prejudicial to the public interest" (Section 1(2) Public Bodies (Admission to Meetings) Act 1960" and all public attendees left the meeting.
14. The Chair then thanked the experts and company representatives for their attendance, participation and contribution to the appraisal and they left the meeting.

## **Part 2 – Closed session**

15. Discussion on confidential information continued. This information was supplied by the company.
16. The Evidence Review Group representatives left the meeting.
17. The Committee continued to discuss the clinical and cost effectiveness of ixekizumab for treating moderate to severe plaque psoriasis.

- 17.1. The committee decision was based on consensus.
18. The Committee instructed the technical team to prepare the Appraisal Consultation Document (ACD) in line with their decisions.

**Appraisal of lenalidomide for the treatment of multiple myeloma in people who have received at least one prior therapy with bortezomib (partial review of TA171) [ID667]**

**Part 1 – Open session**

19. The Chair welcomed company representatives from Celgene to the meeting.
20. The Chair asked all Committee members to declare any relevant interests
  - 20.1. Dr Amanda Adler, Dr Sanjeev Patel, Dr Ray Armstrong, Dr Jeff Aronson, Professor John Cairns, Mr Mark Chapman, Dr Neil Iosson, Dr Rebecca Kearney, Mr Christopher O'Regan, Professor Stephen Palmer, Professor John Pounsford, Dr Nigel De-Kare Silver, Dr Marta Soares, Professor Ken Stein, Mr David Thomson and Mr Nigel Westwood all declared that they knew of no personal specific financial interest, personal non-specific financial interest, non-personal specific financial interest, non-personal non-specific financial interest, personal specific family interest or personal non-specific family interest for any of the technologies to be considered as part of the appraisal of lenalidomide for the treatment of multiple myeloma in people who have received at least one prior therapy with bortezomib (partial review of TA171) [ID667].
21. The Chair asked all NICE Staff to declare any relevant interests.
  - 21.1. All declared that they knew of no personal specific financial interest, personal non-specific financial interest, non-personal specific financial interest, non-personal non-specific financial interest, personal specific family interest or personal non-specific family interest for any of the technologies to be considered as part of the appraisal of lenalidomide for the treatment of multiple myeloma in people who have received at least one prior therapy with bortezomib.
22. The Chair asked all other invited guests (assessment group/ERG and invited experts, not including observers) to declare their relevant interests.
  - 22.1. Nicola Huxley and Professor Martin Hoyle declared that they knew of no personal specific financial interest, personal non-specific financial interest, non-personal specific financial interest, non-personal non-specific financial interest, personal specific family interest or personal non-specific family interest for any of the technologies to be considered as part of the appraisal of lenalidomide for the treatment of multiple myeloma in people who have received at least one prior therapy with bortezomib.
23. The Chair introduced the key themes arising from the consultation responses to the Appraisal Consultation Document (ACD) received from consultees, commentators and through the NICE website.

24. The Chair asked the company representatives whether they wished to comment on any matters of factual accuracy.
25. The Chair explained that "representatives of the press and other members of the public be excluded from the remainder of this meeting having regard to the confidential nature of the business to be transacted, publicity on which would be prejudicial to the public interest" (Section 1(2) Public Bodies (Admission to Meetings) Act 1960)" and all public attendees left the meeting.
26. The Chair then thanked the Evidence Review Group and company representatives for their attendance, participation and contribution to the appraisal and they left the meeting.

## **Part 2 – Closed session**

27. The Committee continued to discuss the clinical and cost effectiveness of lenalidomide for the treatment of multiple myeloma in people who have received at least one prior therapy with bortezomib.
  - 27.1. The committee decision was based on consensus.
28. The Committee instructed the technical team to prepare the Appraisal Consultation Document or Final Appraisal Determination (FAD) in line with their decisions.

## **Mepolizumab for treating severe eosinophilic asthma [ID798]**

### **Part 1 – Open session**

29. The Chair welcomed company representatives from GlaxoSmithKline to the meeting.
30. The Chair asked all Committee members to declare any relevant interests
  - 30.1. Dr Amanda Adler, Dr Sanjeev Patel, Dr Ray Armstrong, Dr Jeff Aronson, Professor John Cairns, Mr Mark Chapman, Dr Neil Iosson, Dr Rebecca Kearney, Mr Christopher O'Regan, Professor Stephen Palmer, Professor John Poundsford, Dr Nigel De-Kare Silver, Dr Marta Soares, Professor Ken Stein and Mr Nigel Westwood all declared that they knew of no personal specific financial interest, personal non-specific financial interest, non-personal specific financial interest, non-personal non-specific financial interest, personal specific family interest or personal non-specific family interest for any of the technologies to be considered as part of the appraisal of lenalidomide for the treatment of multiple myeloma in people who have received at least one prior therapy with bortezomib (partial review of TA171) [ID667].
31. The Chair also asked all Committee members to declare any relevant interests for the appraisal of ibrutinib for treating chronic lymphocytic leukaemia [ID749] as this discussion would not have a part 1.
  - 31.1. Dr Amanda Adler, Dr Sanjeev Patel, Dr Ray Armstrong, Dr Jeff Aronson, Professor John Cairns, Mr Mark Chapman, Dr Neil Iosson, Dr Rebecca Kearney, Mr Christopher O'Regan, Professor Stephen Palmer, Professor John Poundsford, Dr Nigel De-Kare Silver, Dr Marta Soares, Professor Ken Stein, Mr David Thomson and Mr Nigel Westwood all declared that they knew of no personal specific financial interest, personal non-specific

financial interest, non-personal specific financial interest, non-personal non-specific financial interest, personal specific family interest or personal non-specific family interest for any of the technologies to be considered as part of the appraisal of ibrutinib for treating chronic lymphocytic leukaemia [ID749].

32. The Chair asked all NICE Staff to declare any relevant interests.
  - 32.1. All declared that they knew of no personal specific financial interest, personal non-specific financial interest, non-personal specific financial interest, non-personal non-specific financial interest, personal specific family interest or personal non-specific family interest for any of the technologies to be considered as part of the appraisals of mepolizumab for treating severe eosinophilic asthma and ibrutinib for treating chronic lymphocytic leukaemia [ID749].
33. The Chair asked all other invited guests (assessment group/ERG and invited experts, not including observers) to declare their relevant interests.
  - 33.1. Matt Stevenson and Inigo Bermejo declared that they knew of no personal specific financial interest, personal non-specific financial interest, non-personal specific financial interest, non-personal non-specific financial interest, personal specific family interest or personal non-specific family interest for any of the technologies to be considered as part of the appraisal of mepolizumab for treating severe eosinophilic asthma.
34. The Chair introduced the key themes arising from the consultation responses to the Appraisal Consultation Document (ACD) received from consultees, commentators and through the NICE website.
35. The Chair asked the company representatives whether they wished to comment on any matters of factual accuracy.
36. The Chair explained that "representatives of the press and other members of the public be excluded from the remainder of this meeting having regard to the confidential nature of the business to be transacted, publicity on which would be prejudicial to the public interest" (Section 1(2) Public Bodies (Admission to Meetings) Act 1960" and all public attendees left the meeting.
37. The Chair then thanked the Evidence Review Group and company representatives for their attendance, participation and contribution to the appraisal and they left the meeting.

## **Part 2 – Closed session**

38. The Committee continued to discuss the clinical and cost effectiveness of mepolizumab for treating severe eosinophilic asthma.
  - 38.1. The committee decision was based on consensus.
39. The Committee instructed the technical team to prepare the Final Appraisal Determination (FAD) in line with their decisions.

**Part 1 – Open Session:** There was no Part 1 – Open Session.

**Part 2 – Closed Session**

40. The Chair gave a presentation on the new information submitted by the company and on the Evidence Review Group critique of this information.
41. The Committee continued to discuss the clinical and cost effectiveness of Ibrutinib for treating chronic lymphocytic leukaemia [ID749].
  - 41.1. The committee decision was based on consensus.
42. The Committee instructed the technical team to prepare the Final Appraisal Determination (FAD) in line with their decisions.

**Date, time and venue of the next meeting:** Wednesday 2 November, 10am at Prospero House, 241 Borough High Street, London SE1 1GA